The UK drugs regulator has approved Eisai and Biogen's Alzheimer's disease therapy Leqembi, shortly after an EU committee turned it down on the grounds that its modest efficacy did not outweigh ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback